Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin
Chronic hepatitis C virus genotype 6 infection: Response to pegylated interferon and ribavirin
复制标题
DOI：
10.1086/591252
复制
发表时间：
2008-09-15
影响因子：
6.4
通讯作者：
Yuen, Man-Fung
中科院分区：
文献类型：
--
作者：
Fung, James;Lai, Ching-Lung;Yuen, Man-Fung
背景迄今为止，没有研究评价聚乙二醇干扰素治疗慢性丙型肝炎病毒（HCV）基因型6感染。我们的目的是确定聚乙二醇干扰素联合利巴韦林治疗基因型6与基因型1感染的疗效。方法. 42例慢性HCV感染患者（基因型1，n = 21;基因型6，n = 21）用聚乙二醇干扰素α-2a（n = 20）或α-2b（n = 22）联合口服利巴韦林治疗48周.结果基因型1和6在早期病毒学应答率（76% vs. 81%; P > 0.05）和治疗结束应答率（71% vs. 81%; P > 0.05）方面没有差异。感染基因型6的患者的持续病毒学应答率（SVR）高于感染基因型1的患者（86% vs. 52%; P = 0.019）。两个基因型组的总体不良反应特征相似.接受聚乙二醇干扰素α-2a和α-2b治疗的患者之间的SVR率没有显著差异。多变量分析显示，基因型是与SVR相关的唯一显著因素（P = 0.039）。结论.用聚乙二醇干扰素和利巴韦林治疗48周，基因型6感染的患者比基因型1感染的患者SVR率显著更高。需要进一步的研究来确定较低剂量和24周的治疗是否足以治疗基因型6感染。
Background. To date, no study has evaluated pegylated interferon for the treatment of chronic infection with hepatitis C virus (HCV) genotype 6. We aimed to determine the efficacy of pegylated interferon plus ribavirin for treating infection with genotype 6 versus genotype 1. Methods. Forty- two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon alpha-2a (n = 20) or alpha-2b (n = 22) combined with oral ribavirin for 48 weeks. Results. There was no difference between genotypes 1 and 6 in the rates of early virological response (76% vs. 81%; P >.05) and end-of-treatment response (71% vs. 81%; P >.05). Patients infected with genotype 6 had a higher rate of sustained virological response (SVR) than did patients infected with genotype 1 (86% vs. 52%; P = .019). The overall adverse- effects profile was similar in both genotype groups. There was no significant difference in the rate of SVR between patients receiving pegylated interferon alpha- 2a and those receiving alpha- 2b. Multivariate analysis showed that genotype was the only significant factor associated with SVR (P = .039). Conclusions. Treatment with pegylated interferon and ribavirin for 48 weeks resulted in a significantly higher rate of SVR in patients infected with genotype 6 than in those infected with genotype 1. Further studies are required to determine whether lower dosages and 24 weeks of therapy may be sufficient for the treatment of genotype 6 infection.